Medical Developments International (ASX:MVP) Risk Assessment

View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Medical Developments International is: High Risk: High uncertainty.

Competitive Comparison of Medical Developments International's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Developments International's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Risk Assessment falls into.

Medical Developments International (ASX:MVP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Medical Developments International Risk Assessment Related Terms

Thank you for viewing the detailed overview of Medical Developments International's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Medical Developments International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

MDDVF:USA

Address

4 Caribbean Drive, Scoresby, VIC, AUS, 3179

Website

https://www.medicaldev.com

Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International Headlines

From GuruFocus

Roundhill Announces Two Fund Closures

By PRNewswire PRNewswire • 03-18-2022

Medical Developments International Stock Appears To Be Possible Value Trap

By GF Value • 01-01-1970